home / stock / knbif / knbif quote
Last: | $0.0975 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0975 |
Close: | $0.0975 |
High: | $0.0975 |
Low: | $0.0975 |
Volume: | 7,000 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0975 | $0.0975 | $0.0975 | $0.0975 | $0.0975 | 7,000 | 07-17-2024 |
$0.1036 | $0.1036 | $0.1036 | $0.1036 | $0.1036 | 1,000 | 07-12-2024 |
$0.109 | $0.110046 | $0.109 | $0.110046 | $0.109 | 3,000 | 07-11-2024 |
$0.1123 | $0.121 | $0.1123 | $0.121 | $0.1123 | 1,600 | 07-08-2024 |
$0.111 | $0 | $0.111 | $0 | $0 | 15 | 07-05-2024 |
$0.111 | $0.111 | $0.111 | $0.111 | $0.111 | 7,000 | 06-27-2024 |
$0.105852 | $0.10516 | $0.105852 | $0.1062 | $0.1 | 89,000 | 06-26-2024 |
$0.09309 | $0.09309 | $0.09309 | $0.09309 | $0.09309 | 100 | 06-20-2024 |
$0.094654 | $0.094654 | $0.094654 | $0.094654 | $0.094654 | 6,900 | 06-07-2024 |
$0.1048 | $0.1048 | $0.1048 | $0.1048 | $0.1048 | 2,500 | 05-27-2024 |
$0.1048 | $0.1048 | $0.1048 | $0.1048 | $0.1048 | 2,500 | 05-24-2024 |
$0.110969 | $0.115 | $0.110969 | $0.115 | $0.110969 | 7,500 | 05-23-2024 |
$0.1091 | $0.1091 | $0.1091 | $0.1091 | $0.1091 | 50,005 | 05-21-2024 |
$0.10105 | $0.099555 | $0.10105 | $0.10105 | $0.099555 | 10,000 | 05-17-2024 |
$0.0939 | $0 | $0.0939 | $0 | $0 | 5 | 05-15-2024 |
$0.0939 | $0.0939 | $0.0939 | $0.0939 | $0.0939 | 550 | 05-01-2024 |
$0.0898 | $0.094 | $0.0898 | $0.094 | $0.0898 | 84,000 | 04-12-2024 |
$0.106 | $0.121 | $0.106 | $0.12277 | $0.106 | 14,401 | 04-10-2024 |
$0.1122 | $0.1122 | $0.1122 | $0.1122 | $0.1122 | 2,000 | 04-09-2024 |
$0.1122 | $0.1122 | $0.1122 | $0.1122 | $0.1122 | 2,000 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
WINNIPEG, Manitoba, July 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has received ISO 13485:2016 Medical Device Single Audit Program (“MDSAP”) Quality Certification as a designer, de...
WINNIPEG, Manitoba, July 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed a worldwide license agreement with Arizona-based Omni Bioceutical Innovations Inc. (“Omni”) for its c...
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product (“revyve™”...